Cowden Syndrome Market 2019 |Worldwide Analysis, Business Growth, Industrial Outlook, Global Key Players, Emerging Trends with Forecast till 2023
Cowden syndrome (CS), a clinical disorder and inherited condition
that is characterized primarily by multiple, noncancerous growths called
hamartomas on various parts of the body.
The occurrence of CS can lead to the risk of developing certain types of
cancer including Breast, thyroid, and endometrial cancers.
Get free sample @ https://www.marketresearchfuture.com/sample_request/5096
Acknowledging the traction, the market is vibrating with
currently, Market Research Future (MRFR) in its recently published study report
asserts that the global Cowden syndrome market gaining further prominence will
demonstrate a spectacular growth by 2023, surpassing its previous growth
records in terms of value with a striking 6.7% CAGR during 2017 – 2023.
The Cowden syndrome market still consists of a limited
number of treatments; however, governments of various countries have taken up
many initiatives to spread the awareness and to support the manufacturers for
research and development of drugs, medical devices, and technology. These
initiatives are paying off well by increasing the market size substantially,
raising the awareness among people about the disease and the availability of
its treatments.
Global Cowden Syndrome Market – Segments
The MRFR analysis is segmented into four key dynamics;
By Sites : Breast, Thyroid, Endometrium (uterus),
Colorectal, Kidney, and Skin (melanoma), among others.
By Treatments :
Genetic Testing, Chemotherapy (Anthracyclines, Taxanes, Antimetabolites,
Alkylating Agents and others.), Targeted Therapy (Monoclonal Antibodies,
Tyrosine Kinase Inhibitors, and others.), Surgery & Radiation Therapy,
Hormone Therapy (Selective Estrogen-Receptor Modulators (SERMs), Aromatase
Inhibitors, and others.).
By End-Users : Hospital & Clinics, ambulatory care
centers, and others.
By Regions : North America, Europe, APAC and the
Rest-of-the-World.
Global Cowden Syndrome Market – Regional Analysis
The North American region dominates the global Cowden
syndrome market, accounting for a significant market share. The region is
expected to continue with its dominance throughout the forecast period. The
increasing prevalence of Cowden syndrome and cancer is predominantly driving
the market growth in the region.
Additional factors acting as a tailwind to the market growth
include high healthcare expenditure, huge technological development, and strong
government support for research & development. Simultaneously, the presence of the leading
players and increasing availability of funds are impacting the market growth in
this region, positively.
The European region accounts for the second-largest market
for Cowden syndrome treatment, emerging as another lucrative market, globally.
Germany, backed by its sizeable medical device industry and its vast Cowden syndrome
treatment market is expected to drive the market growth in the region.
Favorable governmental support and initiatives drive the growth in the market
extensively. The proliferating healthcare sector in the region, backed by the
resurging economy is fostering the market growth radiantly.
Global Cowden Syndrome Market – Competitive Analysis
Cowden syndrome market is highly competitive. The key
strategies traced from the analysis of recent developments of the key players
include product launch, agreement & partnership, acquisition, and
expansion. Key manufacturers utilizing breakthrough manufacturing technology
strive to develop a comprehensive range of safe and reliable solutions
portfolio.
Key Players:
The global cowden syndrome market is driven by some of the
leading players including GlaxoSmithKline Plc. (UK), Novartis AG (Switzerland),
Bayer AG (Germany), Eli Lilly and Company (US), Amgen, Inc. (US), AstraZeneca
Plc. (UK), Sanofi (France), Bristol-Myers Squibb Company (US), AbbVie Inc.
(US), Takeda Pharmaceuticals (Japan), Spectrum Pharmaceuticals Inc. (US),
Pfizer, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co.,
Inc. (US), Janssen Biotech, Inc. (US), Oncomed Pharmaceuticals (US), and
Immunomedics (US).
Industry/Innovation/ Related News:
September 21, 2018 - GlaxoSmithKline Plc. (UK), a leading
global research-based pharmaceutical and healthcare company partnering with the
Tres Cantos Open Lab Foundation (TCOLF), a company addressing the translational
and funding gap existing in Global Health (GH) announce additional £5m funding
for open innovation research in diseases including rear diseases such as Cowden
syndrome impacting the developing world.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact:
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com
Comments
Post a Comment